VECTIVBIO HLDG AG's ticker is VECT and the CUSIP is H9060V101. A total of 52 filers reported holding VECTIVBIO HLDG AG in Q2 2023. The put-call ratio across all filers is 0.68 and the average weighting 1.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $5,303,928 | – | 314,400 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CHI Advisors LLC | 5,492,893 | $47,595,916 | 12.68% |
| TCG Crossover Management, LLC | 2,333,300 | $20,218,045 | 3.57% |
| CAXTON CORP | 156,222 | $1,346,055 | 3.44% |
| VR Adviser, LLC | 1,866,000 | $16,168,890 | 2.72% |
| Vivo Capital, LLC | 2,333,300 | $20,218 | 2.33% |
| Novo Holdings A/S | 3,339,484 | $28,919,931 | 1.81% |
| Cormorant Asset Management, LP | 2,536,617 | $21,980 | 1.47% |
| Orbimed Advisors | 7,006,861 | $60,714,451 | 1.16% |
| Bpifrance SA | 2,806,217 | $24,315,870 | 0.80% |
| Frazier Life Sciences Management, L.P. | 1,333,400 | $11,480,574 | 0.71% |